The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000803392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
19/06/2026
Date registered
Help: Date registered
3/07/2026
Date last updated
Help: Date last updated
31/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
3/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effectiveness of a Virtual Reality Walking Program for Spinal Cord Injury Neuropathic Pain Over the Medium to Long Term.
Scientific title
Are analgesic effects of virtual reality just a flash in the pan? A replicated single-case experimental design examining the effects of a VR Walking simulator over medium-to-long term follow-up in people with neuropathic pain following SCI
Additional trial identifiers [1] 316052 0
Nil Known
Universal Trial Number (UTN)
U1111-1332-2690
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Spinal cord injury related neuropathic pain 339921 0
Condition category
Condition code
Physical Medicine / Rehabilitation 336147 336147 0 0
Physiotherapy
Neurological 338551 338551 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Description of the intervention
Participants will use a Virtual Reality headset to complete a virtual walking experience. VRWalk app (Immersive Experience Labs, USA) is an immersive, embodied virtual walking experience. Participants will complete vitual walking using the VRwalk app for 20 minutes five times per week during the intervention periods. Participants will be assisted with the first session by the primary researcher (a qualified Physiotherapist) for familiarisation. The participant will be supported during the first week to gradually build up to the full 20-minute session length in the absence of any adverse effects.

Procedures
The study has an ABABC design, A refers to the non-intervention phases, B will be the intervention phases. C phase will be used as an assessment of feasibility. The first A phase will be a baseline phase of approximately two weeks. This will be followed by the first 4-week intervention phase. After this first intervention phase there will be a 3-4 week wash out phase (22-26 days), during which participants will no longer have access to the VRWalk intervention. After the wash out phase, participants will begin a second 4-week intervention phase, identical in structure and instructions to the first. This will be followed by a 2-week maintenance phase, during which participants will continue to have access to the device and app but will not be prompted or encouraged to use it. Usage during this phase is optional.

Mode of delivery
The intervention will be delivered through a virtual reality head mounted display. Using this device participants will access the VRWalk app and be prompted to walk and explore the virtual world.

Location
All intervention sessions will be conducted at the participants home.

Personalisation/adaption
While the intervention will not be personalised in a targetted way participants can explore the virtual world at their own pace throughout the intervention, therefore have control over their speed and exploration. Additionally, participants will be free to use the VR more than the amount previously mentioned so will be able to increase their dosage if they find it effective.

Adhearence and fidelity
Adherence data collected via the headset (frequency and duration of use). Participants will be contacted at least once per week to monitor progress, troubleshoot technical issues, and provide support.
Intervention code [1] 334467 0
Behaviour
Intervention code [2] 334469 0
Rehabilitation
Description of the comparator or control
As this is a replicated single case experimental design there will be no control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345829 0
Pain Severity
Timepoint [1] 345829 0
Daily throughout the study.
Primary outcome [2] 345830 0
Adherence
Timepoint [2] 345830 0
Measured throughout the study when participants use the app
Secondary outcome [1] 463431 0
Participant Experience
Timepoint [1] 463431 0
End of each intervention phase
Secondary outcome [2] 463432 0
Pain Interference
Timepoint [2] 463432 0
Baseline and end of each phase
Secondary outcome [3] 463433 0
Neuropathic Pain Quality
Timepoint [3] 463433 0
Baseline and end of each phase
Secondary outcome [4] 463434 0
Embodiment in VR
Timepoint [4] 463434 0
Daily on VR app usage.
Secondary outcome [5] 463435 0
Presence in VR
Timepoint [5] 463435 0
Daily on VR app usage
Secondary outcome [6] 463436 0
Medication Use
Timepoint [6] 463436 0
Baseline and end of each phase
Secondary outcome [7] 463437 0
App usability
Timepoint [7] 463437 0
End of each intervention phase
Secondary outcome [8] 463438 0
Impression of change
Timepoint [8] 463438 0
End of each phase
Secondary outcome [9] 463439 0
Pain Self Efficacy
Timepoint [9] 463439 0
Baseline and End of each phase
Secondary outcome [10] 463441 0
Participant experience of VR
Timepoint [10] 463441 0
End of intervention phases
Secondary outcome [11] 463442 0
Psychological wellbeing
Timepoint [11] 463442 0
Baseline and end of each phase
Secondary outcome [12] 463444 0
Left Right Descrimination
Timepoint [12] 463444 0
Baseline and end of intervention 1
Secondary outcome [13] 463446 0
Motor Imagery
Timepoint [13] 463446 0
Baseline and end of intervention 1
Secondary outcome [14] 463911 0
Pain Severity
Timepoint [14] 463911 0
Baseline and end of each phase

Eligibility
Key inclusion criteria
Diagnosis of a spinal cord injury
Ability to independently swing arms
Minimum of 1 year post injury
Age 18-65 years
Persistent (>3months) at or below level neuropathic pain according to ISCIP Classification
Pain severity of at least 6/10 for worst pain and at least 4/10 for average pain.
DN4 score at least 4
Stable medication regimen in the past month
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Significant arm pain (>4/10) or impairment on arm movement
History of moderate or severe traumatic brain injury
Severe psychiatric disorder (e.g. Schizophrenia)
Significant sensitivity to light
Significant cognitive impairments
Inability to understand and communicate in English.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Sample size justification: A purposive sample of five individuals living with spinal cord injury-related neuropathic pain will be recruited. This sample size exceeds the minimum recommended three replications for single-case experimental designs and aligns with studies using similar designs, populations, and interventions.

Analysis:
The data analysis for the primary outcome ( Pain) will incorporate both systematic visual analysis and quantitative statistical analysis (Morley, 2017). The process used will be based on the six-outcome process A) level, B) trend, C) variability, D) immediacy of effect, E) overlap and F) consistency of patterns. These will be assessed within and then between phases. Data will be analysed initially on a within participant basis and then extended to a between participant basis to assess for consistency of result.
This visual analysis will be complemented with quantitative statistical analyses to strengthen interpretation of intervention effects. Statistical analysis will employ multiple approaches. As recommended for reversal designs, both weighted pooled standardized mean difference (pSMD) and the positive effects ratio will be calculated.
To complement these measures, Tau-U analyses will be conducted for each adjacent phase comparison (e.g., A1–B1, B1–A2) and then pooled within participants and across the study.
In addition to this statistical method, we will assess the number of participants that have achieved minimally important change (MIC). For the pain measure this will be set at 30% improvement, which is in line with consensus values for more treatable conditions.

Adherence will be described descriptively with respect to frequency and duration and will be compared to planned usage. This will be analyzed and reported on both an individual and study level. Feasibility will be analysed and presented primarily through the criteria presented in the a-priori feasibility table, as well as descriptively. The secondary analysis and generalization measures will be reported descriptively and assessed using MIC or minimally clinically important difference (MCID) for each participant individually and again aggregated to group level.

Morley, S. (2017). Single case methods in clinical psychology: A practical guide (1st ed.). Routledge.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 320653 0
University
Name [1] 320653 0
Adelaide University
Country [1] 320653 0
Australia
Primary sponsor type
University
Name
Adelaide University
Address
Country
Australia
Secondary sponsor category [1] 323281 0
None
Name [1] 323281 0
Address [1] 323281 0
Country [1] 323281 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319193 0
University of South Australia Human Research Ethics Committee
Ethics committee address [1] 319193 0
Ethics committee country [1] 319193 0
Australia
Date submitted for ethics approval [1] 319193 0
28/10/2025
Approval date [1] 319193 0
27/11/2025
Ethics approval number [1] 319193 0
207274

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 146558 0
Mr Daniel Van Der Laan
Address 146558 0
Adelaide University, Corner of North Terrace and, Frome Rd, Adelaide SA 5001
Country 146558 0
Australia
Phone 146558 0
+612 8 8302 1265
Fax 146558 0
Email 146558 0
Contact person for public queries
Name 146559 0
Daniel Van Der Laan
Address 146559 0
Adelaide University, Corner of North Terrace and, Frome Rd, Adelaide SA 5001
Country 146559 0
Australia
Phone 146559 0
+612 8 8302 1265
Fax 146559 0
Email 146559 0
Contact person for scientific queries
Name 146560 0
Dr Daniel Harvie
Address 146560 0
Adelaide University, Corner of North Terrace and, Frome Rd, Adelaide SA 5001
Country 146560 0
Australia
Phone 146560 0
+612 8 8302 1265
Fax 146560 0
Email 146560 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Daniel Van Der Laan - [email protected]
Dr Daniel Harvie - [email protected]


Are there extra considerations when requesting access to individual participant data?
Yes: Subject to Adelaide University policies. All requests will be assessed on a case by case basis.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.